FDA Inspections Ombudsman Could Help Foreign Manufacturers
This article was originally published in The Gold Sheet
Executive Summary
New ORA position intended to help get questions answered, but already being used to smooth inspection issues.
You may also be interested in...
GDUFA II: Inspection Information Takes Center Stage
Sponsors say transparency is important as generic drug user fee negotiations move to inspection policy.
If At First You Don’t Succeed, Try Dispute Resolution
More companies are turning to CDER’s formal appeals process when presented with a review division’s regulatory decision or advice. Even though few appeals are granted in full, many sponsors get valuable clarity on a path forward; some appeals, like that for Amarin’s Vascepa SPA, are turned away at the door.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.